Cargando…
Dasatinib-induced massive left chylothorax in a patient with chronic myeloid leukemia
Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia. One common adverse event associated with dasatinib use is fluid retention, includi...
Autores principales: | Makimoto, Go, Misawa, Mahito, Maeda, Yoshinobu, Kiura, Katsuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108759/ https://www.ncbi.nlm.nih.gov/pubmed/35585905 http://dx.doi.org/10.1016/j.rmcr.2022.101662 |
Ejemplares similares
-
Diagnostic Pitfalls of Chylothorax After Dasatinib Treatment of Chronic Myeloid Leukemia
por: Kelly, Ryan L., et al.
Publicado: (2022) -
Dasatinib-Related Chylothorax
por: Huang, Yen-Min, et al.
Publicado: (2015) -
Dasatinib-associated chylothorax in a pediatric patient with chronic myeloid leukemia: a case report and literature review
por: Liu, Qinqin, et al.
Publicado: (2023) -
Dasatinib‐induced chylothorax in a patient with chronic myeloid leukaemia: a case report and literature review
por: Hsu, Chao‐Chin, et al.
Publicado: (2021) -
DASATINIB-RELATED CHYLOTHORAX
por: Young, Katherine, et al.
Publicado: (2019)